EFFECT OF SATVAVAJAYCHIKITSA (COUNSELLING AND ASSURANCE) AND SHIRODHARA IN THE MANAGEMENT OF PSYCHOGENIC ERECTILE DYSFUNCTION: A CASE STUDY

Any stimulus (intrinsic or extrinsic) that triggers a biological response is known as stress. Stress can exert various negative effects on the body ranging from alterations in homeostasis to life-threatening effects and death. Erectile dysfunction can be a manifestation of chronic stress. ED is the most common male sexual dysfunction that affects 10-25% of middle-aged and elderly men. ED may result from many etiologic factors like psychogenic, endocrino- logic, neurogenic, arteriogenic or venoocclusive dysfunction. These factors are not mutually exclusive and multi- ple factors contribute to ED in many patients. According to modern science Psychogenic factors frequently coex- ist with other etiologic factors and should be considered in all cases. A patient aged 35 years came to the OPD of A&U Tibbia college with complaints of inability to initiate and maintain erection along with abnormal vision, dizziness, retrosternal burning, indigestion, heaviness in chest and disinterest. He was advised for Shirodhara along with counselling (Satvvajaychikitsa) and after a couple of days, there was a significant improvement in pa- tient. In this case study, we are trying to highlight the contribution of stress & psyche on male sexual dysfunction and its management through Satvavajaychikitsa (counselling) and Shirodhara. Keywords: Erectile dysfunction, Satvavajaychikitsa, Shirodhara.

Clinical Pharmacokinetic Evaluation of Optimized Liquisolid Tablets as a Potential Therapy for Male Sexual Dysfunction

The study aimed at developing a liquisolid tablet (LST) containing tadalafil (TDL) and dapoxetine (DPX) with improved bioavailability as a potential therapy for male sexual dysfunction. A mixture of nonvolatile solvents, namely PEG 200 and Labrasol®, was utilized to prepare LSTs that were assessed for their quality characteristics. The Box–Behnken design (BBD) was employed to statistically explore the effect of the formulation factors on the quality attributes of LSTs. Furthermore, an in vivo pharmacokinetic study was carried out for the optimized LST in comparison with the marketed tablets on healthy human volunteers. The optimized LST revealed acceptable quality limits with enhanced dissolution for both APIs. The pharmacokinetic parameters after oral administration of the optimized LST indicated that the Cmax of TDL in LSTs was 122.61 ng/mL within 2h compared to the marketed tablets, which reached 91.72 ng/mL after 3 h, indicating the faster onset of action. The AUC was improved for TDL in LST (4484.953 vs. 2994.611 ng/mL∙h in the marketed tablet) and DPX in LST (919.633 vs. 794.699 ng/mL∙h in the marketed tablet). This enhancement in bioavailability potentially minimizes the associated side effects and improves the treatment of male sexual dysfunction, particularly for diabetic patients.